Device Trial Radar · NCT01761006
Evaluation of FeNO During and Following Acute COPD Exacerbation
Last checked: Nov 19, 2026Latest source record: Nov 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10
Actual
Start
Mar 2013
Primary completion
Sep 23, 2014
Study completion Sep 23, 2014
Sponsor
- Lead sponsor
- Wake Forest UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aerocrine AB
- First posted
- Jan 4, 2013
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to determine whether exhaled nitric oxide (FeNO) goes up during an acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and whether the level of exhaled nitric oxide returns to normal in the weeks after an exacerbation.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
NIOX MINO®Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in FeNO from Day 0 to the end of the studyTime frame: Time points for measurement of the Primary Endpoint will be between Day 0 (considered baseline) and Visit 2/Day 14, Visit 3/Day 28 and Visit 4/Day 56.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.